Anti-Inflammatory drug could stop blood cancer before it starts

NCT ID NCT05641831

Recruiting now Prevention Sponsor: Uma Borate Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether canakinumab, a drug that reduces inflammation, can prevent blood cancer in people with CCUS—a condition where low blood counts and genetic mutations raise cancer risk. About 110 adults with high-risk CCUS will receive either canakinumab or a placebo. The study aims to see if the drug delays or stops progression to leukemia or related cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Canakinumab
What this could lead to: If it works, this could point toward a way to prevent blood cancers in people with CCUS by targeting inflammation.
What could go wrong: This is an early phase II trial with only 110 participants, so results may not apply to everyone. The drug may not stop cancer progression and could have side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

clonal hematopoiesis of indeterminate potential myeloid neoplasm prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLONAL CYTOPENIA OF UNDETERMINED SIGNIFICANCE

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Ohio State University Comprehensive Cancer Center
RECRUITING

Columbus, Ohio, 43210, United States
UT Southwestern Medical Center at Dallas
RECRUITING

Dallas, Texas, 75235, United States
University of Miami
RECRUITING

Miami, Florida, 33136, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37232, United States
Weill Cornell Medical College
RECRUITING

New York, New York, 10021, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.